Laurent Fischer

Former Chief Executive Officer at Ocera Therapeutics, Inc. (Inactive)

Laurent Fischer

Laurent Fischer

Former Chief Executive Officer at Ocera Therapeutics, Inc. (Inactive)

Overview
Career Highlights

Rxcentric, Inc.
Tobira Therapeutics, Inc.
Jennerex Biotherapeutics, Inc.

RelSci Relationships

742

Number of Boards

12

Birthday

1964

Age

55

Contact Data
Trying to get in touch with Laurent Fischer? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Laurent Fischer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at Domain Associates LLC

Relationship likelihood: Strong

President & Chief Operating Officer at Syndax Pharmaceuticals, Inc.

Relationship likelihood: Strong

Secretary at Tobira Therapeutics, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Mirum Pharmaceuticals, Inc.

Relationship likelihood: Strong

Managing General Partner at Frazier Management LLC

Relationship likelihood: Strong

President & Chief Executive Officer at CTI BioPharma Corp.

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at CTI BioPharma Corp.

Relationship likelihood: Strong

General Partner at Canaan Management, Inc.

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

General Partner at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Paths to Laurent Fischer
Potential Connections via
Relationship Science
You
Laurent Fischer
Former Chief Executive Officer at Ocera Therapeutics, Inc. (Inactive)
Education
MD Unknown

University of Geneva is a public research university located in Geneva, Switzerland.

Career History
Senior Vice President, Head of the Liver Therapeutic Area
2016 - Prior

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Chief Executive Officer
2015 - Prior

Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on May 4, 2015 and is headquartered in South San Francisco, CA.

President, Chief Executive Officer & Director
2012 - Prior

Jennerex Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA.

Boards & Committees
Member, Steering Committee
2016 - Current
President, Chief Executive Officer & Director
2012 - Prior

SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$1,000 - $4,999
2008

AIDS Healthcare Foundation is a non-profit organization which provides medicine and advocacy programs for HIV/AIDS. The firm offers HIV and STD testing, thrift store, dental clinic, and healthcare center services. The company was founded by Michael Weinstein in 1987 and is headquartered in Los Angeles, CA.

$100 - $999
2005

AIDS Healthcare Foundation is a non-profit organization which provides medicine and advocacy programs for HIV/AIDS. The firm offers HIV and STD testing, thrift store, dental clinic, and healthcare center services. The company was founded by Michael Weinstein in 1987 and is headquartered in Los Angeles, CA.

$100 - $999
2004

AIDS Healthcare Foundation is a non-profit organization which provides medicine and advocacy programs for HIV/AIDS. The firm offers HIV and STD testing, thrift store, dental clinic, and healthcare center services. The company was founded by Michael Weinstein in 1987 and is headquartered in Los Angeles, CA.

Political Donations
$2,500
2012

Former President of United States

$250
2004

Former Senator from Massachusetts

Transactions
Details Hidden

Ocera Therapeutics, Inc. (Inactive) raised money in a private placement transaction

Investments
Details Hidden

Ocera Therapeutics, Inc. is a San Diego based, privately held biopharmaceutical company founded in January 2005 by Dr. Eckard Weber and Dr. Laurent Fischer. Ocera focuses on the development of novel therapeutics in the areas of liver and gastrointestinal diseases.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Laurent Fischer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Laurent Fischer's profile does not indicate a business or promotional relationship of any kind between RelSci and Laurent Fischer.